Cempra (CEMP) Added to Focus List at Roth Capital
Get Alerts CEMP Hot Sheet
Rating Summary:
1 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Roth Capital analyst Debjit Chattopadhyay added Cempra, Inc. (NASDAQ: CEMP) to its Focus List. The firm maintained a Buy rating and price target of $42.
Chattopadhyay commented, "Based on the robust readout from the Solitaire Oral study, expectations have ratcheted higher heading into the IV data (expected during 4Q). A statistically-significant benefit (older, sicker patients) could be a big win, with positive ramifications for pricing and adoption especially in the hospital setting, in our view. Solithromycin (pediatric, COPD, gonorrhea, NASH) or Taksta (ABSSI, B&J infections) are compelling opportunities and not reflected in the stock, in our opinion."
For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.
Shares of Cempra, Inc. closed at $36.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 29Metals Ltd (29M:AU) PT Lowered to AUD0.50 at RBC Capital
- AO World Plc. (AO/:LN) PT Raised to GBP1.25 at Jefferies
- Home Depot (HD) PT Raised to $360 at Telsey, 'in the long term, Home Depot should remain a winner in retail'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!